AGA expert review on HCC surveillance: preventing cirrhosis is the best strategy; semiannual ultrasound plus α-fetoprotein remains preferred for at-risk patients; novel biomarkers such as GALAD are not yet ready for routine use and multicancer blood tests should not be used.
Guideline
Rich et al. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review